Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology

European Neuropsychopharmacology

Volumn 26, Issue 1, 2016, Pages 3-14

  Neill, Jo C ^a   Grayson, Ben ^a   Kiss, Béla ^b   Gyertyán, István ^b   Ferguson, Paul ^c   Adham, Nika ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GEDEON RICHTER LTD   (Hungary)

^c Prescott Medical Communications Group   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cariprazine; Cognition; Dopamine D3 receptor; Negative symptoms; Phencyclidine (PCP); Schizophrenia

Indexed keywords

CARIPRAZINE; RISPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PHENCYCLIDINE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; LEARNING; LISTER HOODED RAT; LOCOMOTION; NEGATIVE SYNDROME; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; SYMPTOMATOLOGY; ANIMAL; COGNITION; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; INSTRUMENTAL CONDITIONING; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PRECLINICAL STUDY; PSYCHOLOGY; RECOGNITION; SOCIAL BEHAVIOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EXPLORATORY BEHAVIOR; FEMALE; MOTOR ACTIVITY; NOOTROPIC AGENTS; PHENCYCLIDINE; PIPERAZINES; RATS; RECOGNITION (PSYCHOLOGY); RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 84959172345     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.11.016     Document Type: Article

References (68)

1. Abdul-Monim Z., Neill J.C., Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. 2007, 21:198-205.
2. Abdul-Monim Z., Reynolds G.P., Neill J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol. 2003, 17:57-65.
3. Adham N., Gyertyán I., Kiss B., Idris N., McLean S., Grayson B., Yoshitake T., Kehr J., Neill J. Cariprazine attenuates PCP-induced increases in extracellular prefrontal cortical glutamate levels and improves PCP-induced deficits in cognition and social behavior. Eur. Neuropsychopharmacol. 2012, 22(Suppl 2):S347.
4. Barnes S.A., Sawiak S.J., Caprioli D., Jupp B., Buonincontri G., Mar A.C., Harte M.K., Fletcher P.C., Robbins T.W., Neill J.C., Dalley J.W. Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int. J. Neuropsychopharmacol. 2014, 18(2):1-12. 10.1093/ijnp/pyu010.
5. Black K.J., Hershey T., Koller J.M., Videen T.O., Mintun M.A., Price J.L., Perlmutter J.S. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc. Natl. Acad. Sci. USA 2002, 99:17113-17118.
6. Bobes J., Garcia-Portilla M.P., Bascaran M.T., Saiz P.A., Bousono M. Quality of life in schizophrenic patients. Dialogue Clin. Neurosci. 2007, 9:215-226.
7. Boulougouris V., Dalley J.W., Robbins T.W. Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behav. Brain Res. 2007, 179:219-228.
8. Bustillo J., Galloway M.P., Ghoddoussi F., Bolognani F., Perrone-Bizzozero N. Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy. Neurochem. Int. 2012, 61:128-131.
9. Cahill L. Why sex matters for neuroscience. Nat. Rev. Neurosci. 2006, 7:477-484.
10. Caravaggio F., Blumberger D., Nakajima S., Mulsant B., Graff-Guerrerero A. Occupancy of dopamine D3 receptors by aripiprazole in treatment resistant late-life depressed patients depends on length of treatment as evidenced by in vivo imaging with [11C]-(+)-PHNO. Am. J. Geriatr. Psychitary 2014, 22:S83-S84.
11. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J. Clin. Psychiatry 2014, 75(Suppl 1):S21-S26.
12. Cotel M.C., Lenartowicz E.M., Natesan S., Modo M.M., Cooper J.D., Williams S.C., Kapur S., Vernon A.C. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. Eur. Neuropsychopharmacol 2015, 25(11):2098-2107.
13. Debelle M., Németh G., Szalai E., Szatmári B., Harsányi J., Barabássy Á., Laszlovszky I. Eur. Neuropsychopharmacol. 2015, 25(Suppl 2):S510.
14. Duman R.S., Duric V., Banasr M., Adham N., Kiss B., Gyertyán I. Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology 2012, 38(S1):S84.
15. Durgam S., Cutler A.J., Lu K., Migliore R., Ruth A., Laszlovszky I., Németh G., Meltzer H.Y. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 2015, In press.
16. Durgam S., Starace A., Li D., Migliore R., Ruth A., Németh G., Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr. Res. 2014, 152:450-457.
17. Gobert A., Rivet J.M., Audinot V., Cistarelli L., Spedding M., Vian J., Peglion J.L., Millan M.J. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 1995, 275:899-913.
18. Graff-Guerrero A., Mamo D., Shammi C.M., Mizrahi R., Marcon H., Barsoum P., Rusjan P., Houle S., Wilson A.A., Kapur S. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch. Gen. Psychiatry 2009, 66:606-615.
19. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 2007, 184:31-38.
20. Grayson B., Leger M., Piercy C., Adamson L., Harte M., Neill J.C. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav. Brain Res. 2015, 285:176-193.
21. Gross G., Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb. Exp. Pharmacol 2012, 213:167-210.
22. Gross G., Wicke K., Drescher K.U. Dopamine D(3) receptor antagonism - still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386:155-166.
23. Gururajan A., Taylor D.A., Malone D.T. Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav. Pharmacol. 2010, 21:690-709.
24. Gyertyán I., Sághy K., Laszy J., Elekes O., Kedves R., Gémesi L.I., Pásztor G., Zájer-Balázs M., Kapás M., Csongor E.Á., Domány G., Kiss B., Szombathelyi Z. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378:529-539.
25. Gyertyán I., Kiss B., Sághy K., Laszy J., Szabó G., Szabados T., Gémesi L.I., Pásztor G., Zájer-Balázs M., Kapás M., Csongor E.Á., Domány G., Tihanyi K., Szombathelyi Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int. 2011, 59:925-935.
26. Hertzmann M., Reba R.C., Kotlyarov E.V. Single photon emission computed tomography in phencyclidine and related drug abuse. Am. J. Psychiatry 1990, 147:255-256.
27. Jenkins T.A., Harte M.K., McKibben C.E., Elliott J.J., Reynolds G.P. Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behav. Brain Res. 2008, 194:230-235.
28. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
29. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997, 17:92-99.
30. Joyce J.N., Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 2005, 10:917-925.
31. Kalkstein S., Hurford I., Gur R.C. Neurocognition in schizophrenia. Curr. Top. Behav. Neurosci. 2010, 4:373-390.
32. Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K., Laszlovszky I., Durgam S. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J. Clin. Psychopharmacol. 2015, 35:367-373.
33. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A., Investigators C., Neurocognitive Working G. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
34. Kiss B., Laszlovszky I., Horváth A., Némethy Z., Schmidt E., Bugovics G., Fazekas K., Gyertyán I., Agai-Csongor E., Domány G., Szombathelyi Z. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378:515-528.
35. Kiss B., Horváth A., Némethy Z., Schmidt E., Laszlovszky I., Bugovics G., Fazekas K., Hornok K., Orosz S., Gyertyán I., Ágai-Csongor E., Domány G., Tihanyi K., Adham N., Szombathelyi Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 2010, 333:328-340.
36. Knuesel I., Chicha L., Britschgi M., Schobel S.A., Bodmer M., Hellings J.A., Toovey S., Prinssen E.P. Maternal immune activation and abnormal brain development across CNS disorders. Nat. Rev. Neurol. 2014, 10(11):643-660.
37. Leger M., Alvaro G., Large C.H., Harte M.K., Neill J.C. Efficacy of AUT6, a novel and selective Kv3 channel modulator, to alleviate cognitive and neurobiological dysfunction in the sub-chronic PCP rat model of schizophrenia symptomatology. J. Psychopharmacol. Suppl. 2015, 29(8):A66.
38. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 1959, 81:363-369.
39. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
40. McLean S.L., Woolley M.L., Thomas D., Neill J.C. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology 2009, 206:403-414.
41. McLean S.L., Neill J.C., Idris N.F., Marston H.M., Wong E.H., Shahid M. Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav. Brain Res. 2010, 214:240-247.
42. Meltzer H.Y., Rajagopal L., Huang M., Oyamada Y., Kwon S., Horiguchi M. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 2013, 16:2181-2194.
43. Millan M.J., Fone K., Steckler T., Horan W.P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur. Neuropsychopharmacol. 2014, 24:645-692.
44. Millan M.J., Svenningsson P., Ashby C.R., Hill M., Egeland M., Dekeyne A., Brocco M., Di Cara B., Lejeune F., Thomasson N., Munoz C., Mocaer E., Crossman A., Cistarelli L., Girardon S., Iob L., Veiga S., Gobert A. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J. Pharmacol. Exp. Ther. 2008, 324:600-611.
45. Mizrahi R., Agid O., Borlido C., Suridjan I., Rusjan P., Houle S., Remington G., Wilson A.A., Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr. Res. 2011, 131:63-68.
46. Morris B.J., Cochran S.M., Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 2005, 5:101-106.
47. Nakajima S., Gerretsen P., Takeuchi H., Caravaggio F., Chow T., Le Foll B., Mulsant B., Pollock B., Graff-Guerrero A. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 2013, 23:799-813.
48. Neill J.C., Harte M.K., Haddad P.M., Lydall E.S., Dwyer D.M. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur. Neuropsychopharmacol. 2014, 24:822-835.
49. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., Snigdha S., Rajagopal L., Harte M.K. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 2010, 128:419-432.
50. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
51. Pantelis C., Barber F.Z., Barnes T.R., Nelson H.E., Owen A.M., Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr. Res. 1999, 37:251-270.
52. Papp M., Gruca P., Lason-Tyburkiewicz M., Adham N., Kiss B., Gyertyan I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav. Pharmacol. 2014, 25:567-574.
53. Rajagopal L., Massey B.W., Huang M., Oyamada Y., Meltzer H.Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr. Pharm. Des. 2014, 20:5104-5114.
54. Reynolds L.M., Cochran S.M., Morris B.J., Pratt J.A., Reynolds G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr. Res. 2005, 73:147-152.
55. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
56. Savilla K., Kettler L., Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust. N. Z. J. Psychiatry 2008, 42:496-504.
57. Semkovska M., Bedard M.A., Stip E. Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives. Encephale 2001, 27:405-415.
58. Slifstein M., Abi-Dargham A., D'Souza D.C., R.E.C., Laszlovszky I., Durgam S., Adham N., Kiss B., Gyertyán I., Kapás M., Lee Y. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical pet study with [11C]-(+)-PHNO. Neuropsychopharmacology 2013, 38:S520.
59. Snigdha S., Neill J.C. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. Behav. Brain Res. 2008, 187:489-494.
60. Snigdha S., Neill J.C. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav. Brain Res. 2008, 191:26-31.
61. Snigdha S., Idris N., Grayson B., Shahid M., Neill J.C. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology 2011, 214:843-853.
62. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., Meltzer H.Y. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
63. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5:25-43.
64. Sutcliffe J.S., Marshall K.M., Neill J.C. Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav. Brain Res. 2007, 177:117-125.
65. Tsapakis E.M., Dimopoulou T., Tarazi F.I. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol. Ther. 2015, 153:135-147.
66. Wessinger W.D. Sexual dimorphic effects of chronic phencyclidine in rats. Eur. J. Pharmacol. 1995, 277:107-112.
67. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo 1991, 11:47-48.
68. Zimnisky R., Chang G., Gyertyán I., Kiss B., Adham N., Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology 2013, 226:91-100.